Results 151 to 160 of about 16,307,830 (290)

Other title: House Bill 2843 - Testimony on Behalf of the Citizens' Utility Ratepayer Board by David Springe, Consumer Counsel

open access: yes, 2004
application/pdf; "March 9, 2004."; Testimony before the Kansas Legislature, House Taxation Committee, presented by David Springe, Consumer Counsel, Citizens' Utility Ratepayer Board."Testimony "to support H.B.
Springe, David.
core  

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

open access: yesMolecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner   +14 more
wiley   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Other title: House Bill 2881 - Testimony on Behalf of the Citizens' Utility Ratepayer Board by David Springe, Consumer Counsel

open access: yes, 2008
application/pdf; "February 25, 2008."; Testimony before the Kansas Legislature, House Utilities Committee, presented by David Springe, Consumer Counsel, Citizens' Utility Ratepayer Board.Testimony in opposition to House Bill 2881.
Springe, David.
core  

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Other title: House Bill 2278 - Testimony on Behalf of the Citizens' Utility Ratepayer Board by Steve Rarrick, Staff Attorney

open access: yes, 2007
application/pdf; "February 6, 2007."; Testimony before the Kansas Legislature, House Utilities Committee, presented by Steve Rarrick, Staff Attorney, Citizens' Utility Ratepayer Board.Testimony in opposition to House Bill 2278.
Rarrick, Steve (Craig Steven).
core  

Home - About - Disclaimer - Privacy